![International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2008.307/MediaObjects/41375_2009_Article_BFleu2008307_Fig1_HTML.jpg)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Leukemia
![Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/97343738-f909-4e28-94e4-b624973cd798/hsr2113-fig-0001-m.jpg)
Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library
Freelite® Human Kappa Free kit For use on the Roche Cobas Integra® For in vitro diagnostic use Product Code: LK016.RI
Verification of Newly FDA-Approved Kappa and Lambda Free Light Chain Assays on a Previously Untested Platform
![Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia - Pratt - 2009 - British Journal of Haematology - Wiley Online Library Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia - Pratt - 2009 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/2f33e782-175c-449a-a910-b20f370eb6ed/bjh_7456_f1.gif)
Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia - Pratt - 2009 - British Journal of Haematology - Wiley Online Library
Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation | Haematologica
![Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis](https://www.degruyter.com/document/doi/10.1515/cclm-2015-0799/asset/graphic/j_cclm-2015-0799_fig_002.jpg)
Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis
![Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/10154338-ee7f-4b52-aec0-62fdf281e1c4/hsr2113-fig-0002-m.jpg)
Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library
![PDF) Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney diesease on haemolysis PDF) Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney diesease on haemolysis](https://www.researchgate.net/profile/Carel-Pretorius/publication/287483244/figure/tbl1/AS:669264314912777@1536576455670/FLC-assay-results-pre-and-post-haemodialysis_Q320.jpg)
PDF) Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney diesease on haemolysis
![Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia - Pratt - 2009 - British Journal of Haematology - Wiley Online Library Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia - Pratt - 2009 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/0d445cf1-df2f-42ed-8716-fb607cb21ea6/bjh_7456_f2.gif)
Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia - Pratt - 2009 - British Journal of Haematology - Wiley Online Library
![Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c86c0fb5-0da8-451e-af81-d2ade967b08e/hsr2113-fig-0004-m.jpg)
Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease - Yang - 2019 - Health Science Reports - Wiley Online Library
Serum free light chain assays (Freelite®) are recommended by the NCCN Clinical Practice Guidelines in Oncology and the Internat
Serum free light chain assays (Freelite®) are recommended by the NCCN Clinical Practice Guidelines in Oncology and the Internat
![PDF) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS) PDF) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS)](https://www.researchgate.net/profile/Dirk-Larson/publication/7883288/figure/tbl2/AS:601807722127390@1520493550610/Absolute-Risk-of-Progression-of-MGUS-to-Myeloma-or-Related-Disorders-Based-on-the-Serum_Q320.jpg)